Olio Labs

Emerging

SF AI drug discovery company identifying multi-protein combination therapeutics 4x faster at 90% lower cost; YC S23 $4.5M Boom Capital Series A with in vivo/vitro results competing with Recursion for combination therapy AI.

Company Overview

About Olio Labs

Olio Labs is a San Francisco-based computational drug discovery company using AI and machine learning to identify multi-protein combination therapeutics for complex diseases — targeting biological pathways where single-target drugs fail because the disease involves multiple protein interactions simultaneously. Founded in 2023 and backed by Y Combinator (S23) with $5 million raised including a $4.5 million Series A led by Boom Capital and Overwater Ventures in March 2025, Olio Labs' combination therapeutics platform has demonstrated in vivo and in vitro superiority over existing market drugs, with a discovery process claimed to be 4x faster and 90% lower cost than traditional drug development approaches.

Business Model & Competitive Advantage

Olio Labs' multi-protein targeting approach addresses a fundamental limitation in drug development: most diseases — particularly cancer, autoimmune disorders, and neurological conditions — are driven by dysregulation across multiple protein pathways simultaneously. Single-target drugs (kinase inhibitors, checkpoint inhibitors) achieve partial response but face resistance as tumor cells activate compensatory pathways. Olio Labs' AI platform models protein interaction networks to identify combination therapies — selecting multiple agents that simultaneously target complementary pathway vulnerabilities — predicting synergistic drug combinations that human researchers cannot systematically explore across the combinatorial space of available compounds.

Competitive Landscape 2025–2026

In 2025, Olio Labs competes in the AI drug discovery and combination therapeutics market with Recursion Pharmaceuticals (NASDAQ: RXRX, large-scale phenomics and ML drug discovery), Insilico Medicine (AI generative drug design), and Relay Therapeutics (NASDAQ: RLAY, protein motion-based drug design) for AI-powered drug discovery positioning. The combination therapeutics field has validated market analogs — Pfizer's KRAS G12C inhibitor combination trials and cancer immunotherapy combinations have demonstrated that multi-agent oncology regimens outperform monotherapy. Olio Labs' YC-backing places it in the computational biotech community intersecting AI and drug discovery. The 2025 strategy focuses on identifying lead combination candidates for clinical development partnerships with pharmaceutical companies, generating additional preclinical proof-of-concept data, and raising Series B funding to advance the most promising combinations into IND-enabling studies.

Revenue
$4.5M
Curated content • Fact-checked and verified
Loading News...
Loading Culture...

Open Positions

Reddit Discussions

Loading Competitive Intelligence...

Key Differentiators

Emerging Innovator

Olio Labs is an emerging player bringing innovative solutions to the Healthcare market.

Frequently Asked Questions

Not So Random Others

Oda Studio

Real Estate & Property Tech
B2bProptechAi PoweredSaas

Oda Studio is a United States-based AI-powered interior design platform — backed by Y Combinator (W20) — providing homebuyers, renters, and design enthusiasts with AI tools to discover their personal

Armilla AI

Insurance Tech
B2bSaasInsuranceAi Powered

Armilla AI is a third-party AI quality assurance and warranty company that evaluates AI models for organizations deploying AI in regulated or high-stakes contexts — assessing models against EU AI Act

Campfire

Finance
B2bSaasAi PoweredFintechAutomationStartup

Campfire is a United States-based AI-native enterprise resource planning (ERP) company — backed by Y Combinator (S23) with $38.5 million raised including a $35 million Series A led by Accel in June 20

Hermes Robotics

Manufacturing
B2bHardwareManufacturingAi PoweredAutomationStartup

Hermes Robotics is an autonomous mobile robot (AMR) and warehouse automation company developing robots and software for logistics and fulfillment operations in warehouses, distribution centers, and ma

Duckie

Infrastructure
B2bPlatformAi PoweredAutomation

Duckie is a San Francisco-based AI customer support platform — backed by Y Combinator (W24) with $500,000 in funding from Y Combinator, Andreessen Horowitz, Greylock, KungHo Fund, Netflix, and 5 addit

Zeffy

Nonprofit Tech
B2bSaas

Zeffy is a Montreal-based fundraising platform for nonprofit organizations that charges zero platform fees on donations — asking donors to optionally contribute a tip to cover Zeffy's operating costs

Compare Olio Labs with Competitors

Side-by-side AI visibility scores, platform breakdown, and market position.

For Olio Labs

Claim This Profile

Are you from Olio Labs? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.

Claim Olio Labs Profile →
For competitors & analysts

Track AI Visibility in Real Time

Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Olio Labs vs competitors. Get alerts when AI recommendations shift.

Start Free Tracking →